清咳平喘颗粒治疗痰热郁肺型咳嗽的临床疗效观察  

Clinical observation of Qingke Pingchuan Granules in treatment of phlegm heat stagnation lung type cough

作　　者：徐向前[1] 张晔敏[1] 毕蓉蓉[1] 郭晓燕[1] 薛鸿浩[1] 张惠勇[1] 陆城华 XU Xiang-qian;ZHANG Ye-min;BI Rong-rong;GUO Xiao-yan;XUE Hong-hao;ZHANG Hui-yong;LU Cheng-hua(Department of Respiratory Medicine,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院呼吸内科,上海200032

出　　处：《中草药》2023年第15期4928-4933,共6页Chinese Traditional and Herbal Drugs

基　　金：上海市卫生健康委员会科研项目(ZY-SYJS-3);上海中医药大学2022年度应对奥密克戎感染新型冠状病毒肺炎应急攻关项目(第2批,2022YJ-12);上海中医药大学附属龙华医院优秀青年人才临床能力提升计划(第3批,RC-2020-01-09)。

摘　　要：目的观察清咳平喘颗粒治疗痰热郁肺型咳嗽的临床有效性。方法选取2020年1月—2021年6月上海中医药大学附属龙华医院呼吸科门诊就诊的痰热郁肺型咳嗽患者100例,按随机数字表法分为对照组和治疗组各50例,对照组为西医常规治疗,治疗组在西医常规治疗基础上联合清咳平喘颗粒治疗。两组均连续治疗2周。观察两组患者治疗前后的中医证候、咳嗽症状、气道反应(血清免疫球蛋白E、外周血嗜酸性粒细胞)、肺功能[最大呼气流量、第1秒用力呼气容积(forced expiratory volume for 1 second,FEV1)与用力肺活量(forced vital capacity,FVC)的比值]、生活质量及不良反应情况。结果治疗后,对照组和治疗组的总有效率分别是90%、94%,两组比较差异无统计学意义(P>0.05)。治疗后,两组患者中医证候评分、日间及夜间咳嗽积分较治疗前降低,且治疗组明显低于对照组(P<0.05)。治疗后,两组血清免疫球蛋白E、外周血嗜酸性粒细胞较治疗前明显下降,且治疗组气道反应指标改善好于对照组(P<0.05)。治疗后,两组最大呼气流量、FEV1/FVC较治疗前明显上升(P<0.05),但两组比较差异无统计学意义(P>0.05)。随访时两组患者的生活质量评分较治疗前均显著升高,治疗组评分改善优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗期间两组均未发生不良反应。结论清咳平喘颗粒在治疗痰热郁肺型咳嗽安全性良好,有助于改善咳嗽症状,改善肺通气,提高患者生活质量。Objective To observe the clinical efficacy of Qingke Pingchuan Granules(清咳平喘颗粒)in the treatment of phlegm heat stagnation lung type cough.Methods A total of 100 patients with phlegm heat stagnation lung type cough treated in the respiratory department of Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine from January 2020 to June 2021 were selected and divided into control group and treatment group with 50 cases each.The control group was treated with conventional western medicine,and the treatment group was treated with Qingke Pingchuan Granules on the basis of conventional western medicine.Both groups were treated continuously for two weeks.The traditional Chinese medicine(TCM)symptoms,cough symptoms,airway reaction(serum immunoglobulin E,peripheral blood eosinophils),lung function[maximum expiratory flow,the ratio of forced expiratory volume for one second(FEV1)to forced vital capacity(FVC)],quality of life and adverse reactions of the two groups before and after treatment.Results After treatment,the total effective rates of the control group and the treatment group were 90% and 94%,respectively,and there was no statistically significant difference between the two groups(P>0.05).After treatment,the TCM syndrome score,daytime and nighttime cough score of the two groups were significantly lower than those before treatment,and the treatment group was significantly lower than the control group(P<0.05).After treatment,serum immunoglobulin E and peripheral blood eosinophils in both groups were significantly decreased compared with those before treatment,and airway response indexes in the treatment group were better than those in the control group(P<0.05).After treatment,the maximum expiratory flow and FEV1/FVC increased compared with those before treatment(P<0.05),but there was no significant difference between the two groups(P>0.05).During the follow-up,the quality of life scores of patients in the two groups were significantly higher than those before treatment,and the s

关 键 词：痰热郁肺型咳嗽 清咳平喘颗粒 中成药 FEV1/FVC 生活质量 

分 类 号：R285.64[医药卫生—中药学]